Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

Achtnichts, Lutz; Chan, Andrew; Czapliński, Adam; Pasquier, Renaud Du; Findling, Oliver; Gobbi, Claudio; Hoepner, Robert; Kamber, Nicole; Kamm, CP; Kuhle, Jens; Lalive, Patrice H.; Lutterotti, Andreas; Martin, Roland; Müller, Stefanie; Papadopoulou, Athina; Pot, Caroline; Salmen, Anke; Schippling, Sven; Zecca, Chiara

doi:10.1177/2514183x18822073

Cited by 6 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, 17 drugs are approved for MS treatment in Germany (for an overview of the respective drugs and their modes of action, see Table 1; for specifics in Switzerland refer to Achtnichts and colleagues). 2,13–18…”

Section: Introductionmentioning

confidence: 99%

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Wiendl

Gold

Berger

et al. 2021

Ther Adv Neurol Disord

123

101

View full text Add to dashboard Cite

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

show abstract

Section: Introductionmentioning

confidence: 99%

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Wiendl

Gold

Berger

et al. 2021

Ther Adv Neurol Disord

123

101

View full text Add to dashboard Cite

show abstract

“…9 Adjustment for region is justified by the country-specific label of FTY considering 1st-(Switzerland) vs 2nd-line treatment (Europe: Germany and Greece), which might have had the greatest influence on our analysis. 10 Patients were identified in the centers using predefined terms to search the existing local clinical information systems (figure). No other selection criteria were set.…”

Section: Discussionmentioning

confidence: 99%

Dimethyl fumarate vs fingolimod following different pretreatments

Diem

Daponte

Findling

et al. 2020

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

ObjectiveDespite frequent use of fingolimod (FTY) and dimethyl fumarate (DMF), studies comparing clinical efficacy and withdrawal rates of DMF and FTY concerning different pretreatment situations are rare. The aim of our study was to compare relapse occurrence and withdrawal rates of DMF and FTY in different pretreatment situations.MethodsPatients from 4 European centers were retrospectively identified and followed until the 1st relapse after treatment start or if no relapse occurred for a maximum of 2 years. Cox regression analyses adjusted for relapsing-remitting MS (RRMS) disease duration, sex, and region were performed for the following pretreatment situations: treatment naive or injectables or DMF/FTY or natalizumab.ResultsSeven hundred thirty-two patients with RRMS (female/male: 2.4:1.0; DMF n = 409, FTY n = 323) were analyzed. Compared with FTY-treated patients, DMF-treated patients discontinued treatment more frequently mainly because of side effects (DMF/FTY: 29.3%/20.7%). Clinical relapses occurred in 24.5% of the patients within 24 months. Survival analysis demonstrated that compared with FTY treatment, DMF treatment was associated with an adjusted hazard ratio (aHR) for occurrence of relapse of 1.9 (95% CI 1.4–2.6, p < 0.001, n = 732). Stratification into pretreatment groups unmasked a higher relapse risk in DMF patients pretreated with natalizumab (aHR [95% CI] 4.5 [1.9–10.8], p = 0.001, n = 122) or to a lesser extend also in treatment-naive patients (aHR [95% CI] 1.9 [1.01–3.6], p = 0.045, n = 230). No differences were observed in patients pretreated with injectables or the respective other oral drug (injectables: p > 0.05, n = 341; other oral: p > 0.05, n = 39).ConclusionsDMF treatment was associated with higher clinical disease activity compared with FTY treatment. A subgroup analysis suggested beneficial effects of FTY in treatment-naive and patients pretreated with natalizumab.

show abstract

“…Für die Schweiz gelten für die individuellen Medikamente teilweise andere Zulassungs- und Erstattungsbedingungen. Diese sind in einem strukturierten Kommentar in Zusammenarbeit der Schweizerischen Multiple Sklerose Gesellschaft und der Schweizerischen Neurologischen Gesellschaft zusammengefasst [ 1 ].…”

Section: Einleitung Und Hintergrundunclassified

“…x Abb. 1 8 Verlaufsmodifizierende Therapien der MS. 1 Azathioprin ist formal zugelassen, wird allerdings nur noch in den seltensten Fällen angewendet (2. Wahl).…”

Section: Kon K K ɵN ɵ ɵ Uierl R R I L L C I I He Th T T Era R R P a Ienunclassified

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

et al. 2021

View full text Add to dashboard Cite

ZusammenfassungDie Multiple Sklerose ist eine komplexe, autoimmun vermittelte Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie axonalen/neuronalen Schaden. Die Zulassung verschiedener verlaufsmodifizierender Therapien und unser verbessertes Verständnis der Krankheitsmechanismen und -entwicklung in den letzten Jahren haben die Prognose und den Verlauf der Erkrankung deutlich verändert. Diese Aktualisierung der Behandlungsempfehlung der Multiple Sklerose Therapie Konsensus Gruppe konzentriert sich auf die wichtigsten Empfehlungen für verlaufsmodifizierende Therapien der Multiplen Sklerose im Jahr 2021. Unsere Empfehlungen basieren auf aktuellen wissenschaftlichen Erkenntnissen und gelten für diejenigen Medikamente, die in weiten Teilen Europas, insbesondere in den deutschsprachigen Ländern (Deutschland, Österreich, Schweiz), zugelassen sind.

show abstract

Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

Cited by 6 publications

References 20 publications

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Dimethyl fumarate vs fingolimod following different pretreatments

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Contact Info

Product

Resources

About